MC Sciences

MC Sciences is a pre-clinical company developing first-in-class superior therapeutics targeting mast cells in immunology and inflammation. MC Sciences has already progressed to developing best potential candidates for accelerated advancement to DC and IND. Chronically activated mast cells are key drivers of several diseases in immunology and inflammation with high unmet need. The selective and complete silencing of activated mast cells remains a high need. Key asset of MC Sciences is the discovery of a novel mast cell specific receptor that regulates the entire mast cell activity and novel small molecules targeting the receptor that completely and selectively silence mast cells acting upstream of all other receptors (including FceRI, KIT, MRGPRX2). Therefore, our novel small molecule approach is strongly positioned as “next generation” therapeutics based on superior therapeutic potential combined with excellent safety profile, on path to dominate the future therapeutic area of mast cell related diseases. The attractive market and competitive position of MC Sciences is based on: a. First-in-class based on novel discovered and validated biology b. The only complete mast cell silencing with superior therapeutic efficacy and safety c. High probability for clinical success based on extensive human proof-of-concept studies d. Lead program with best potential candidate with strong in vivo and human ex vivo data including head-to-head comparison with KIT and MRGPRX2 e. Significant market potential in several disease indications including dermatology (CSU), respiratory (asthma, COPD), liver fibrosis, GI diseases, eye care, chronic inflammation (MCAS, long covid, fibromyalgia) and rare diseases (mastocytosis) MC Sciences is driven by a world-class team of leading mast cell scientists combined with excellent drug development capabilities, execution excellence and the global leading medical mast cell disease network.